<DOC>
	<DOCNO>NCT00370682</DOCNO>
	<brief_summary>This descriptive study evaluate safety immunogenicity different formulation WRAIR dengue vaccine compare placebo .</brief_summary>
	<brief_title>A Phase II Trial Walter Reed Army Institute Research ( WRAIR ) Live Attenuated Virus Tetravalent Dengue Vaccine Healthy Adults Thailand</brief_title>
	<detailed_description>Subjects randomize one three group . One group receive placebo vaccine two receive different dengue vaccine formation . Each subject receive two dos six month apart . All subject 11 venipuncture 11 visit ( i.e. , screen plus 10 study visit ) period nine month .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female adult 2025 year age ( ≥20 year age ≤25 year age ) time vaccination ; Free obvious health problem establish medical history physical examination enter study ; Written inform consent obtain subject ; Able read Subject Information Sheet Consent Form ; Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit ) enrol study ; female must nonchildbearing potential , i.e . surgically sterilize , childbearing potential , must abstinent adequate contraceptive precaution ( i.e . intrauterine contraceptive device ; oral contraceptive equivalent hormonal contraception , e.g . progestin implantable , cutaneous hormonal patch injectable contraceptive ) 30 day prior vaccination , negative pregnancy test within 48 hour prior vaccination must agree continue precaution 60 day completion vaccination series Pregnant lactate female , plan become pregnant planning discontinue abstinence contraceptive precaution ; History neurological behavioral disorder seizure , exception single febrile seizure childhood ; History drug abuse alcohol consumption ( 2 drink per day ) ; History allergic disease/reaction likely exacerbate component vaccine ; Acute chronic , pulmonary , cardiovascular , hepatic , renal , hematologic endocrine functional defect , determine physical examination laboratory test ; Any confirm suspected immunosuppressive immunodeficient condition seropositive HBsAg , antiHCV antiHIV ; Acute disease time enrollment ( acute disease define presence moderate severe illness without fever ) ; Chronic hepatomegaly , right upper quadrant abdominal pain tenderness ; Chronic splenomegaly , leave upper quadrant abdominal pain tenderness ; Hypertension ; chest pain , palpitation , dizziness , shortness breath , arrhythmias friction rub ; Use investigational nonregistered drug vaccine study vaccine within 30 day precede study vaccine ( include placebo ) plan use study period ; Planned administration vaccine foreseen study protocol period start 30 day first dose study vaccine/placebo end 30 day second dose ; A plan move location prohibit participate trial 9 month initial vaccination ; Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 90 day precede first dose plan administration study period . For corticosteroid , mean prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow ; Administration immunoglobulins and/or blood product within 90 day precede first dose plan administration study period ; Any chronic systemic drug therapy continue study period ( except vitamin/mineral supplement routine treatment gastroesophageal reflux ) ; No easy access fix mobile telephone</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>